Futura Medical

Following the publication of Phase II trial data, Futura Medical announces encouraging results, significant improvements in erectile function scores and a favourable safety profile with its topical drug, MED2005. Read more


Healthcare company, Futura Medical, has announced that it has received a formal notice from Church & Dwight that it intends to terminate the licensing agreement that was originally signed in 2013. Read more


Futura Medical has received all regulatory approvals needed for the efficacy trial of MED2002, its topical gel for the treatment of erectile dysfunction, and pre-screening of patients has begun. Read more